Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

0 Views· 06/29/23

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.

Show more

 0 Comments sort   Sort By


Up next